Fulcrum Therapeutics (FULC) Q3 2026 earnings summary

Executive summary

• Discontinued pociredir in June, ended active R&D and cut the workforce ~85% to nine employees; strategic review led to a proposed merger with Slate.

• Merger expected to close in Q4 2026, subject to stockholder approval and other conditions; a $275M aggregate cash dividend to pre-merger stockholders is planned, subject to adjustment.

Financial highlights

• Q3 2026 net loss was $10.9M vs. $19.6M YoY; loss from operations was $13.9M vs. $21.9M.

• Q3 operating expenses were $13.9M vs. $21.9M YoY; R&D fell to $3.0M from $14.3M, while G&A rose to $8.4M from $7.6M.

• 9M 2026 net loss was $56.0M vs. $54.5M YoY; operating expenses increased to $65.4M from $62.1M, including impairment and restructuring charges.

• 9M basic and diluted loss per share was $0.73 vs. $0.87 YoY; no product-sales revenue has been generated.

Outlook and guidance

• Operating expenses and operating cash use are expected to decrease substantially after the pociredir wind-down and restructuring; near-term outflows include restructuring, facility exit and merger-related costs.

• Cash, cash equivalents and marketable securities of $306.5M at September 30, 2026 are expected to fund operating and capital needs for at least 12 months from the report issuance date.

• G&A is expected to decline with reduced headcount, partly offset by merger-related professional fees and ongoing public-company costs; R&D is expected to fall significantly.